Does insulin resistance predict prostate cancer? Results from the REDUCE trials are out – Advanced Prostate Cancer Consensus Conference

Advanced Prostate Cancer Consensus Conference shared a post on LinkedIn:

“Does insulin resistance predict prostate cancer? Results from the Reduction by Dutasteride of Prostate Cancer (REDUCE) Trial out.

This study investigated the association between insulin resistance (measured by HOMA-IR) and Prostate Cancer (PC) risk in participants of the REDUCE trial, a 4-year randomized trial comparing dutasteride with placebo for PC prevention. Among 5,430 men with previous negative biopsies, higher HOMA-IR scores were linked to a lower overall risk of prostate cancer, particularly for low-grade tumors (grade group 1).

However, no significant association was found between HOMA-IR and the risk of high-grade prostate cancer (grade groups 2–5). The findings suggest a potential protective effect of higher HOMA-IR against low-grade PC, though the underlying mechanisms remain unclear.”

Does insulin resistance predict prostate cancer? Results from the Reduction by Dutasteride of Prostate Cancer (REDUCE) Trial

Authors: Renning Zheng, James P. Daniels, Daniel M. Moreira, Shakiba Eslamimehr, Alexis R. Freedland, Lourdes Guerrios-Rivera , Jay H. Fowke and Stephen J. Freedland.

Source: Advanced Prostate Cancer Consensus Conference/LinkedIn